Tactics used by HIV-1 to evade host innate, adaptive, and intrinsic immunities

Chinese Medical Journal

Volumn 126, Issue 12, 2013, Pages 2374-2379

  Lu, Lu ^a   Yu, Fei ^b,c   Du, Lan Ying ^b   Xu, Wei ^a   Jiang, Shi Bo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antibody; Cytotoxic T lymphocytes; Human immunodeficiency virus; Immune evasion; Natural killer

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CXCR4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MANNOSE BINDING LECTIN; NEUTRALIZING ANTIBODY; RANTES; TRIPARTITE MOTIF PROTEIN 5;

ANTIGEN RECOGNITION; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE EVASION; IMMUNE SYSTEM; NATURAL KILLER CELL; REVIEW; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD; CARRIER PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYTIDINE DEAMINASE; GPI-LINKED PROTEINS; HIV-1; HUMANS; IMMUNE EVASION; KILLER CELLS, NATURAL; MONOMERIC GTP-BINDING PROTEINS;

EID: 84879269683     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130121     Document Type: Review

References (61)

1. Steffen I, Pohlmann S. Peptide-based inhibitors of the hiv envelope protein and other class I viral fusion proteins. Curr Pharm Des 2010; 16: 1143-1158.
2. Iaccino E, Schiavone M, Fiume G, Quinto I, Scala G. The aftermath of the Merck's HIV vaccine trial. Retrovirology 2008; 5: 56.
3. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5: 428-434.
4. Wilson NA, Watkins DI. Is an HIV vaccine possible? Braz J Infect Dis 2009; 13: 304-310.
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220.
6. Malim MH, Emerman M. HIV-1 Accessory proteins, ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3: 388-398.
7. Gramberg T, Sunseri N, Landau NR. Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep 2009; 6: 36-42.
8. Gramberg T, Sunseri N, Landau NR. Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep 2009; 6: 36-42.
9. Wolfrum N, Muhlebach MD, Schule S, Kaiser JK, Kloke BP, Cichutek K, et al. Impact of viral accessory proteins of sivsmmpbj on early steps of infection of quiescent cells. Virology 2007; 364: 330-341.
10. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, Rigal D, Et al. Characterization of simian immunodeficiency virus sivsm/ human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol 2008; 82: 12335-12345.
11. Ayinde D, Maudet C, Transy C, Margottin-Goguet F. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology 2010; 7: 35.
12. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey M, et al. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. Plos Pathog 2008; 4: E1000057.
13. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404-1407.
14. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
15. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004; 427: 848-853.
16. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430.
17. Van DN, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3: 245-252.
18. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-661.
19. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-657.
20. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204: 3027-3036.
21. Iannello A, Debbeche O, Samarani S, Ahmad A. Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination. J Leukoc Biol 2008; 84: 27-49.
22. Favoreel HW, Van De Walle GR, Nauwynck HJ, Pensaert MB. Virus complement evasion strategies. J Gen Virol 2003; 84: 1-15.
23. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329: 811-817.
24. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a Gp41-specific human antibody. Nature 2012; 491: 406-412.
25. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337: 183-186.
26. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998; 4: 679-684.
27. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 Gp41. Nature 1997; 387: 426-430.
28. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV Gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659.
29. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV Gp120 envelope glycoprotein. Nature 1998; 393: 705-711.
30. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, et al. CD4-induced conformational changes in the human immunodeficiency virus type 1 Gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998; 72: 4694-4703.
31. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-5094.
32. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes In HIV-1 infection. Nature 1995; 373:123-126.
34. Evans DT, O'Connor DH, Jing P, Dzuris JL, Sidney J, Da SJ, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 1999; 5: 1270-1276.
35. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-860.
36. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. Emerging Cytopathic and antigenic simian immunodeficiency virus variants influence AIDS Progression. Nat Med 1999; 5:535-541.
37. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (Ctls) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205-211.
38. Piguet V, Trono D. Living in oblivion: HIV immune evasion. Semin Immunol 2001; 13: 51-57.
39. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
40. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000; 6: 76-81.
41. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82-85.
42. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004; 427: 848-853.
43. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430.
44. Van DN, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3: 245-252.
45. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response To HIV-1 Vif. Nat Med 2003; 9: 1404-1407.
46. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004; 427: 848-853.
47. Song B. TRIM5alpha. Curr Top Microbiol Immunol 2009; 339: 47-66.
48. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009; 29: 569-580.
49. Van DN, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3: 245-252.
50. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007; 2: 193-203.
51. Strebel K, Klimkait T, Martin MA. A novel gene of HIV-1, Vpu, and its 16-Kilodalton product. Science 1988; 241: 1221-1223.
52. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A, et al. Vpu Serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 2010; 7: 1.
53. Manel N, Littman DR. Hiding in plain sight: how HIV evades innate immune responses. Cell 2011; 147: 271-274.
54. Izquierdo-Useros N, Naranjo-Gomez M, Erkizia I, Puertas MC, Borras FE, Blanco J, et al. HIV and mature dendritic cells: trojan exosomes riding the trojan horse? Plos Pathog 2010; 6: E1000740.
55. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-661.
56. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-657.
57. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007; 4: 2.
58. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-661.
59. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-657.
60. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells. Retrovirology 2012; 9: 87.
61. Wu L. SAMHD1: a new contributor to HIV-1 restriction in resting CD4+ T-Cells. Retrovirology 2012; 9: 88.